Evidence map›Paper›PMID 31526366›Full record

ArticleBMC infectious diseases2019

Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.

Anna Larsen, Vuyolwethu Magasana, Thu-Ha Dinh, Nobubelo Ngandu, Carl Lombard, Mireille Cheyip, Kassahun Ayalew, Witness Chirinda, Gurpreet Kindra, Debra Jackson and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Anna LarsenDivision of Global HIV/AIDS and Tuberculosis, Center for Global Health, US Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Vuyolwethu MagasanaHealth Systems Research Unit, South African Medical Research Council (HSRU, SAMRC), Pretoria, South Africa.
Thu-Ha DinhDivision of Global HIV/AIDS and Tuberculosis, Center for Global Health, US Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Nobubelo NganduHealth Systems Research Unit, South African Medical Research Council (HSRU, SAMRC), Pretoria, South Africa.
Carl LombardHealth Systems Research Unit, South African Medical Research Council (HSRU, SAMRC), Pretoria, South Africa.
Mireille CheyipDivision of Global HIV/AIDS and Tuberculosis, Center for Global Health, US Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Kassahun AyalewDivision of Global HIV/AIDS and Tuberculosis, Center for Global Health, US Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Witness ChirindaHealth Systems Research Unit, South African Medical Research Council (HSRU, SAMRC), Pretoria, South Africa.
Gurpreet KindraDivision of Global HIV/AIDS and Tuberculosis, Center for Global Health, US Centers for Disease Control and Prevention (CDC), Pretoria, South Africa.
Debra JacksonUnited Nations Children's Fund (UNICEF), New York, NY, USA.
Ameena GogaHealth Systems Research Unit, South African Medical Research Council (HSRU, SAMRC), Pretoria, South Africa. ameena.goga@mrc.ac.za.
South African Medical Research Council · ZACenters for Disease Control and Prevention · USUnited Nations Children's Fund · US

Funding

PS08-854, COOPERATIVE AGREEMENT TO THE MRC OF SOUTH AFRICAU2GPS001137 · PS · MEDICAL RESEARCH COUNCIL OF SOUTH AFRICA · PI BHAGWANDIN, NIRESH · 2008 to 2012
$51.1M
Evaluating maternal depression among adolescent and adult women in KenyaF31HD101149 · NICHD · UNIVERSITY OF WASHINGTON · PI LARSEN, ANNA M · 2019 to 2022
$125k
NCHHSTP CDC HHS U2G PS001137NICHD NIH HHS F31 HD101149
6 · The paper itself

Abstract

backgroundDespite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa. We describe ART adherence amongst a cohort of HIV-positive mothers and HIV-exposed but uninfected infants from 6 weeks until 18 months post-delivery and identify risk factors for nonadherence.

methodsData were collected in 2012-2014 through a nationally representative survey of PMTCT effectiveness. Mother-infant pairs were enrolled during the infant's first immunization visit at 6 weeks. Mothers and HIV-exposed infants (2811 pairs) were followed to 18 months at 3-month intervals. Mothers who self-reported being on ART at 6 weeks postpartum (N = 1572 (55.9%)) and infants on NVP at 6 weeks (N = 2370 (84.3%)) were eligible for this analysis and information about their adherence was captured at each interview they attended thereafter. We defined nonadherence within each 3-month interval as self-report of missing > 5% of daily ART/NVP doses, estimated adherence using a Cox survival curve with Andersen & Gill setup for recurring events, and identified risk factors for nonadherence with an extended Cox regression model (separately for mothers and infants) in Stata 13. Results are not nationally representative as this is a subgroup analysis of the follow-up cohort.

resultsAmongst mothers on ART at 6 weeks postpartum, cumulative adherence to maternal ART until 18 months was 63.4%. Among infants on NPV at 6 weeks postpartum, adherence to NVP was 74.5%.. Risk factors for nonadherence to maternal ART, controlling for other factors, included mother's age (16-24 years vs. ≥34 years, adjusted Hazard Ratio (aHR): 1.9, 95% CI: 1.4-2.5), nondisclosure of HIV status to anyone (nondisclosure vs. disclosure: aHR: 1.7, 95% CI: 1.3-2.1), and timing of ART initiation (initiated ART after delivery vs. initiated ART before delivery: aHR: 1.6, 95% CI: 1.3-2.0). Provincial variation was seen in nonadherence to infant NVP, controlling for other factors.

conclusionMaintaining ART adherence until 18 months postpartum remains a crucial challenge, with maternal ART adherence among the six week maternal ART cohort below 65% and infant NVP adherence among breastfeeding infants in this cohort below 75%.This is gravely concerning, given the global policy shift to lifelong ART amongst pregnant and lactating women, and the need for extended infant prophylaxis amongst mothers who are not virally suppressed. Our findings suggest that young mothers and mothers who do not disclose their status should be targeted with messages to improve adherence, and that late maternal ART initiation (after delivery) increases the risk of maternal nonadherence.

Indexed as

InfantMothersPost-Exposure ProphylaxisAdolescentAdultAnti-HIV AgentsBreast FeedingCross-Sectional StudiesFemaleFollow-Up StudiesHIVHIV InfectionsHIV SeronegativityHumansInfectious Disease Transmission, VerticalLactationAnti-HIV AgentsNevirapineHIV-exposed infantsMissed visitsPostnatal care

Identifiers

PMID31526366
PMCPMC6745776
OpenAlexW2972434296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.